financetom
Business
financetom
/
Business
/
RV maker Winnebago beats Q3 profit estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
RV maker Winnebago beats Q3 profit estimates
Jun 25, 2025 4:38 AM

Overview

* Winnebago Adjusted EPS for fiscal Q3 beats analysts' estimates

* Co had previously reported Q3 revenue of $775 mln

* Towable RV segment achieved unit volume growth with new affordable products

Outlook

* Company updates fiscal 2025 guidance: net revenues $2.7 bln to $2.8 bln

* Company expects reported EPS of $0.50 to $1.00 for fiscal 2025

* Adjusted EPS for fiscal 2025 projected at $1.20 to $1.70

* Winnebago sees challenges from uncertain economic environment

Result Drivers

* AFFORDABLE PRODUCTS - Towable RV segment achieved unit volume growth with new affordable offerings, per CEO Michael Happe

* RETAIL SHARE GAINS - Marine segment profitability increased due to continued retail share gains

* PRODUCT MIX - Revenue decline partly due to shift towards lower price-point models, impacting gross profit margin

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $0.81 $0.79

Adjusted

EPS

Q3 EPS $0.62

Q3 Net Miss $17.60 $20.8

Income mln mln

Q3 $46.50

Adjusted mln

EBITDA

Q3 Gross 13.7%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the recreational products peer group is "buy"

* Wall Street's median 12-month price target for Winnebago Industries Inc ( WGO ) is $38.00, about 17.6% above its last closing price of $31.33

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

(This story was created using Reuters automation and AI capabilities based on LSEG and company data. The headline and summary were reviewed by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MoonLake Immunotherapeutics' Skin Disease Drug Hits Key Goals in Phase 3 Trials, Lags Behind UCB Rival
MoonLake Immunotherapeutics' Skin Disease Drug Hits Key Goals in Phase 3 Trials, Lags Behind UCB Rival
Sep 29, 2025
06:44 AM EDT, 09/29/2025 (MT Newswires) -- MoonLake Immunotherapeutics ( MLTX ) said Monday its experimental drug, sonelokimab, met the primary and key secondary endpoints in two Phase 3 trials for moderate-to-severe hidradenitis suppurativa, a chronic inflammatory skin disease. The drugmaker reported that 34.8% and 35.9% of patients treated with sonelokimab achieved the primary endpoint, which is a reduction in...
Microsoft Should 'Immediately Terminate' Lisa Monaco's Employment, Trump Says
Microsoft Should 'Immediately Terminate' Lisa Monaco's Employment, Trump Says
Sep 29, 2025
06:42 AM EDT, 09/29/2025 (MT Newswires) -- Microsoft ( MSFT ) should immediately terminate President of Global Affairs Lisa Monaco, US President Donald Trump said Friday. Monaco has been shockingly hired as the president of global affairs for Microsoft ( MSFT ), in a very senior role with access to highly sensitive information, Trump said in a social media post....
Vistra reaches FID to build two new advanced natural gas power units
Vistra reaches FID to build two new advanced natural gas power units
Sep 29, 2025
Sept 29 (Reuters) - Vistra ( VST ) said on Monday that it had reached a final investment decision to build two natural gas power units, together generating 860 megawatts, at its Permian Basin power plant. (Reporting by Pranav Mathur in Bengaluru; Editing by Anil D'Silva) ...
Enanta's RSV treatment misses main goal in mid-stage study
Enanta's RSV treatment misses main goal in mid-stage study
Sep 29, 2025
Sept 29 (Reuters) - Enanta Pharmaceuticals ( ENTA ) said on Monday its treatment for respiratory syncytial virus failed to shorten the time taken to reduce the severity of some symptoms, missing the primary goal of a mid-stage study. Shares of the company were down nearly 30% in premarket trading. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved